Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-(Hydroxymethyl)benzamidine is a synthetic small molecule belonging to the class of benzyl alcohols and amidines. It features a benzene ring substituted with both a hydroxymethyl group and an amidine group in the para position. The compound is primarily used as an experimental tool in biochemical research rather than as an approved pharmaceutical agent. Its structure suggests potential activity as a serine protease inhibitor—similar to its parent compound benzamidine—but there are no approved medical indications or clinical trial data supporting therapeutic use for any disease[1][2][3][7]. The mechanism of action is presumed to involve reversible inhibition of serine proteases by binding competitively at their active sites.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-(hydroxymethyl)benzamidine.